Risk of vascular endothelial growth factor receptor tyrosine kinase inhibitor induced hepatotoxicity:a network Meta-analysis
10.12173/j.issn.1005-0698.202404061
- VernacularTitle:血管内皮生长因子受体酪氨酸激酶抑制剂肝毒性风险的网状Meta分析
- Author:
Mi JIN
1
;
Chenxiang WANG
;
Zhongjiang YE
;
Ziye ZHOU
Author Information
1. 温州医科大学附属第一医院药学部(浙江温州 325000)
- Publication Type:Journal Article
- Keywords:
Vascular endothelial growth factor receptor tyrosine kinase inhibitor;
Hepatotoxicity;
Network Meta-analysis;
Randomized controlled trials
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(12):1400-1413
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically review the risk of hepatotoxicity caused by vascular endothelial growth factor receptor tyrosine kinase inhibitor(VEGFR-TKI)in clinical practice.Methods PubMed,Embase,CENTRAL,CNKI,WanFang Data and SinoMed databases were electronically searched to collect randomized controlled trials(RCTs)of hepatotoxicity caused by VEGFR-TKI from inception to February 28,2024.Two reviewers independently screened the literature,extracted data and assessed the risk of bias of the included studies.Network Meta-analysis was then performed by Stata 15.0 software.Results A total of 32 RCTs were included,involving 9 kinds of VEGFR-TKI and 12 949 patients.The results of network Meta-analysis showed that compared with placebo,except for a non-significant increase in the risk of alanine aminotransferase(ALT)elevation due to anlotinib,a non-significant increase in the risk of aspartate aminotransferase(AST)elevation due to anlotinib and vandetanib,and a non-significant increase in the risk of total bilirubin(TBIL)elevation due to anlotinib,vandetanib,sorafenib,and lenvatinib,the risks of ALT,AST,and TBIL elevation due to the rest of the VEGFR-TKI were all significantly increased;Pazopanib and apatinib had remarkable increase in the risk of high-grade ALT elevation.Pazopanib,apatinib,sunitinib,sorafenib,and cabozantinib had a remarkable increase in the risk of high-grade AST elevation.Regorafenib had a remarkable increase in the risk of high-grade TBIL elevation.Conclusion VEGFR-TKI can increase the risk of hepatotoxicity in patients,the risks of elevated indicators caused by different VEGFR-TKI are not the same.
